| Website | anadyspharma.com |
| Category | BioTech |
| Employees | |
| Description | Biopharmaceutical Company |
| TOTAL | $17.5M |
| FUNDING TOTAL | $17.5M |
| Venture Round, 6/09 | $17.5M |
Anadys Pharmaceuticals is a biopharmaceutical company dedicated to developing medicines for the treatment of hepatitis C. The company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. Anadys has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.
